Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Oncogene. 2018 Apr 6;37(27):3672–3685. doi: 10.1038/s41388-018-0156-9

Table 1.

In vitro PK parameters

Parameter DMH2 JL5
ClearanceINT (mL/min/kg) 250 129
Plasma protein binding 98.60% 98.30%

From: Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer